Oxford Digital Biomarkers for Dementia (OxDBD): Lean Assessment Process Methodology for Evaluating Clinical Needs, Adoption Barriers, and As Precursor for Early Economic Evaluation and Adoption Strategy in Acute NHS Hospitals

Author(s)

Serres F1, Rose J1, Pendlebury S2, Bajre M3
1Health Innovation Oxford and Thames Valley, Oxford, UK, 2University of Oxford, Oxford, NA, UK, 3Health Innovation Oxford and Thames Valley, Oxford, OXF, UK

OBJECTIVES: To explore the clinical needs, potential usefulness, acceptance and barriers to adoption of the OxDBD risk score for identifying older adults at risk of cognitive decline and dementia in the NHS in England, using the LAP methodology.

METHODS: The Lean Assessment Process (LAP) methodology is a structured process developed to help innovators build evidence early in product development. Stakeholders’ identification and engagement plays a central role, underpinning the identification of unmet clinical needs and potential barriers to adoption of the product. Insights from payers and healthcare professionals are obtained and thematically analysed, highlighting key elements to be considered when designing a clinical trial and cost-effectiveness analysis. Using LAP, we explored the potential usefulness of the OxDBD risk score, designed for use with routinely collected hospital electronic patient record data to identify older hospital patients at short-term risk of developing dementia or cognitive decline. Semi-structured interviews combining qualitative and quantitative questions along with human factors tools were conducted with 17 stakeholders in key roles in the dementia pathway across 14 NHS Trusts in England.

RESULTS: The study showed that stakeholders were positive about the potential usefulness of the OxDBD risk score for identifying older patients at risk of dementia. Interventions tailored to the patient’s risk profile, ability to share the patient’s risk information with other services for prioritizing them in the pathway, planning for future services were perceived as key benefits. However, practical challenges in data collection, EPR integration, clinician reluctance and uncertainties regarding patient preferences were perceived as potential barriers to its adoption.

CONCLUSIONS: The LAP study provided valuable information on the perceived potential usefulness of the OXDBD risk score and its alignment with stakeholders’ preferences. Prototype integration into the workflow for clinical validation/evidence studies to prove its value to end-users will be conducted to support adoption in the NHS dementia pathway.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA186

Topic

Health Technology Assessment, Medical Technologies, Methodological & Statistical Research

Topic Subcategory

Artificial Intelligence, Machine Learning, Predictive Analytics, Value Frameworks & Dossier Format

Disease

Geriatrics, Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×